Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 13, 2018

FDA approves Medtronic’s less-invasive approach to implant LVAD

Medtronic has received US Food and Drug Administration (FDA) approval for the less-invasive implantation procedure of the left ventricular assist device (LVAD) called HeartWare HVAD System intended for advanced, refractory heart failure patients.

Medtronic has received US Food and Drug Administration (FDA) approval for the less-invasive implantation procedure of the left ventricular assist device (LVAD) called HeartWare HVAD System intended for advanced, refractory heart failure patients.

The new approach involves implant of the HVAD System through thoracotomy, where a small lateral, surgical incision is made between the patient’s ribs on the left side of the chest.

Commonly, an LVAD is implanted during a surgical procedure called sternotomy, which requires a vertical incision down the middle of the chest.

FDA approval comes after reviewing findings from the LATERAL prospective clinical trial conducted at 26 US and Canada sites in 144 subjects with end-stage heart failure and eligible for heart transplant.

Medtronic Heart Failure business vice-president and general manager David Steinhaus said: “The thoracotomy approach showed significant improvements in patients’ quality of life and functional capacity, supported by strong safety and effectiveness data from the study.

“The thoracotomy approach showed significant improvements in patients’ quality of life and functional capacity, supported by strong safety and effectiveness data.”

“Further, the added flexibility for implant approach offers a unique advantage of the HVAD System.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

The LATERAL trial met its primary endpoint of non-inferiority of the HVAD implanted via thoracotomy, with 88.1% of subjects experiencing survival at six months being free from disabling stroke, device explant or exchange due to malfunction.

In addition, the key secondary endpoint demonstrated a decrease in total hospital stay duration, from an average of 26.1 days to 18 days.

Data further revealed that overall survival among patients who received an HVAD through the thoracotomy approach was 88.8% at one year.

LATERAL trial principal investigator Edwin McGee said: “We have demonstrated that a thoracotomy is a safe and effective implant technique for the HVAD System, which gives physicians added flexibility in treating a broad range of patients.”

In the US and Europe, the HVAD System can be implanted via both thoracotomy and sternotomy in heart failure patients as a bridge to cardiac transplantation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU